JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib

Blood. 2015 May 21;125(21):3352-3. doi: 10.1182/blood-2015-01-624536.

Affiliations

¹ Laboratorio Congiunto Malattie Mieloproliferative Croniche, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
² Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

PMID: 25999444
DOI: 10.1182/blood-2015-01-624536

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Janus Kinase 2 / genetics*
Nitriles
Polycythemia Vera / drug therapy*
Polycythemia Vera / genetics
Pyrazoles / therapeutic use*
Pyrimidines
Reverse Transcriptase Polymerase Chain Reaction
Thrombocythemia, Essential / drug therapy*
Thrombocythemia, Essential / genetics

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib
JAK2 protein, human
Janus Kinase 2

Associated data

ClinicalTrials.gov/NCT00726232